Company News
Hoersholm; March 13th 2017 – Medical Prognosis Institute will participate with a booth at the event Investordagen Tuesday 21st March from 1.00 – 9.00 pm. Medical Prognosis Institute and Dansk aktionærforening offers investors a free ticket to the event where you can hear Ulla Hald Buhl, IR & Communications telling about MPI and other interesting investor presentations.
If you would like to participate and learn about Medical Prognosis Institute go to – http://butik.shareholders.dk/events/1668-daf/investordagen-i-kobenhavn and click on Register at the top right. In the next picture you use discount code vipmpi2017 and update the basket. Then you can pick up free tickets.
The event will be held at Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen. You can read about the investor event here: http://www.shareholders.dk/investordagen
About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
About MPI’s multiple biomarker called Drug Response Predictor – DRP
MPI’s lead product, the DRP diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP has been tested in 32 trials, where 26 trials showed that drug-specific DRP Biomarkers could predict which patients had a positive effect of the treatment. The DRP platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D. Ulla Hald Buhl, IR & Communication
E-mail: [email protected] E-mail: [email protected]
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
